FULCFulcrum Therapeutics, Inc.同业对比
Fulcrum Therapeutics, Inc. 与Pharmaceutical Preparations的逐项对比:市值、估值、增长、盈利能力、质量与总回报,以及在同业组内的排名。所有数值均由引擎从 SEC 申报与延迟行情计算,排名仅为组内排序位置 —— 描述性数据,非投资建议。
完整同业对比
同业组:同 SIC 行业分类 (Pharmaceutical Preparations)| 公司 | 市值 | 市盈率(TTM) | 市净率 | 市销率 | 营收同比增长 | 净利同比增长 | 息税前利润率 | 净资产收益率 | 投入资本回报率 | 皮氏 F 值 | 一年总回报 | 股息率 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FULC本股 | $288M#8 | — | 0.9x#1 | — | -100.0%#11 | -670.0%#15 | — | -24.1%#4 | — | — | -48.4%#15 | — |
| CYPH | $334M#1 | 4.8x#2 | 2.4x#8 | 222.7x#10 | 0.0%#6 | 107.4%#2 | -2737.8%#10 | 3.6%#2 | — | — | 900.3%#1 | — |
| CATX | $326M#2 | — | 1.0x#2 | 227.7x#11 | — | -30.1%#9 | -7919.4%#12 | -31.8%#6 | -41.0%#1 | — | -5.6%#12 | — |
| QTTB | $324M#3 | 3.5x#1 | 3.1x#10 | 6.0x#3 | — | 162.5%#1 | 31.5%#1 | 28.1%#1 | — | — | 479.3%#2 | — |
| ABEO | $308M#5 | — | 2.4x#9 | 52.9x#7 | — | -211.7%#13 | -1536.9%#9 | -55.6%#9 | -121.6%#2 | — | -4.4%#11 | — |
| VNDA | $305M#6 | — | 1.4x#7 | 1.4x#1 | 8.7%#5 | -1066.7%#16 | -70.0%#3 | -100.1%#11 | — | — | 15.0%#9 | — |
| CTNM | $310M#4 | — | 1.3x#6 | — | -100.0%#11 | -41.9%#10 | — | -25.0%#5 | — | — | 8.4%#10 | — |
| UPB | $290M#7 | — | 1.1x#3 | 101.5x#9 | 20.4%#4 | -128.4%#12 | -5618.8%#11 | -52.9%#8 | — | — | -67.0%#16 | — |
| PYXS | $280M#9 | — | 24.5x#12 | 20.2x#6 | -14.2%#8 | -3.0%#5 | -609.2%#6 | -696.0%#14 | — | — | 52.0%#7 | — |
| CUE | $268M#10 | — | 116.1x#14 | 9.8x#4 | 195.7%#2 | 34.6%#3 | -96.7%#4 | -1151.6%#15 | — | — | 67.1%#4 | — |
| TRDA | $267M#11 | — | 1.1x#5 | 10.5x#5 | -87.9%#10 | -319.0%#14 | -621.1%#7 | -61.6%#10 | — | — | 34.8%#8 | — |
| BCYC | — | — | — | — | 105.8%#3 | -29.5%#8 | -340.4%#5 | -42.9%#7 | -794.1%#3 | — | -46.8%#14 | — |
| LYEL | $260M#13 | — | 1.1x#4 | 7229.0x#12 | -41.0%#9 | 20.0%#4 | -748344.4%#13 | -117.4%#12 | — | — | -14.3%#13 | — |
| CAMP | $258M#14 | — | — | 73.7x#8 | 436.5%#1 | -55.2%#11 | -1502.4%#8 | — | — | — | 58.4%#5 | — |
| GLSI | $261M#12 | — | 83.7x#13 | — | — | -11.2%#6 | — | -621.1%#13 | — | — | 57.1%#6 | — |
| MGNX | $257M#15 | — | 6.0x#11 | 1.7x#2 | -0.3%#7 | -11.4%#7 | -48.7%#2 | -0.2%#3 | — | — | 161.7%#3 | — |
数值来自 SEC 申报与延迟行情;排名仅为该组内的排序位置 —— 描述性数据,不构成评级或建议。 数据构建于 2026-09-17。
数据来自 SEC XBRL 申报与延迟行情 · 排名为组内排序 · 仅供参考 · 非投资建议